Gastrin I (human): Unraveling CCK2 Receptor Signaling in Intestinal Organoids

Introduction

Understanding the complex regulation of gastric acid secretion is central to gastrointestinal physiology studies and the development of novel therapeutics for gastrointestinal disorders. Gastrin I (human) (APExBIO, SKU: B5358) is a highly purified endogenous peptide that has become indispensable for dissecting the gastric acid secretion pathway and probing CCK2 receptor signaling. While previous literature has focused primarily on the peptide’s use in standard in vitro assay systems and its mechanistic synergy with organoid models, this article uniquely evaluates Gastrin I (human) within the context of advanced human pluripotent stem cell-derived intestinal organoids and their translational impact on pharmacokinetic and disease-modeling research. We further provide a comparative analysis of methodological advances, mechanistic depth regarding proton pump activation, and an exploration of how this peptide bridges gaps between traditional and cutting-edge in vitro systems.

Gastrin I (human): Biochemical Properties and Research Utility

Molecular Characteristics and Handling

Gastrin I (human), with CAS number 10047-33-3 and a molecular weight of 2098.22 Da, is supplied as a high-purity (≥98% by HPLC and mass spectrometry), white lyophilized solid by APExBIO. Notably, the peptide is insoluble in water and ethanol but dissolves in DMSO at concentrations ≥21 mg/mL, enabling precise dosing in in vitro applications. For maximum stability, desiccated storage at -20°C is recommended, and solutions should be used promptly due to limited long-term stability.

Mechanistic Role in Gastric Acid Secretion

Gastrin I (human) is an endogenous gastric acid secretion regulator that exerts its physiological effects by binding to the cholecystokinin B (CCK2) receptor on gastric parietal cells. This interaction triggers receptor-mediated signal transduction pathways, culminating in the activation of H⁺/K⁺-ATPase (proton pumps) and a marked increase in gastric acid secretion. The peptide’s specificity and potency as a CCK2 receptor agonist make it an essential tool for exploring intricate aspects of gastrointestinal signaling, especially in experimental models seeking to recapitulate the human gastric environment.

Mechanism of Action: From Receptor Binding to Proton Pump Activation

CCK2 Receptor Signaling Cascade

Upon administration to target cells, Gastrin I (human) binds with high affinity to the CCK2 receptor, a G-protein-coupled receptor (GPCR) predominantly expressed on parietal cells. This ligand-receptor engagement initiates a cascade involving phospholipase C activation, inositol trisphosphate (IP₃) generation, and subsequent intracellular calcium mobilization. The elevated cytosolic calcium triggers the activation of protein kinases that phosphorylate and stimulate the gastric proton pumps. This process is the biochemical cornerstone of proton pump activation and ultimately enhances gastric acid secretion—a phenomenon central to both physiological digestion and the pathogenesis of acid-related disorders.

Unique Aspects in Human-Derived Systems

Much of the foundational work on receptor-mediated signal transduction in gastric tissues has relied on animal models or immortalized cell lines, which may not faithfully recapitulate human-specific responses. The advent of human pluripotent stem cell (PSC)-derived organoids—three-dimensional cultures containing multiple differentiated intestinal cell types—opens new avenues for studying Gastrin I (human) activity in a physiologically relevant context. These organoids not only express functional CCK2 receptors but also reproduce the downstream signaling machinery, allowing detailed dissection of gastric acid secretion pathways in a human-specific, multicellular environment.

Comparative Analysis: Traditional Models Versus Human Intestinal Organoids

Limitations of Conventional In Vitro Systems

Conventional models such as animal gastric tissues and human cancer cell lines (e.g., Caco-2) have long served as platforms for profiling gastric acid secretion and CCK2 receptor agonism. However, these systems are hampered by interspecies variability, incomplete cell-type representation, and aberrant gene expression profiles—especially of drug-metabolizing enzymes and transporters. As noted in prior studies, Caco-2 cells exhibit significantly lower levels of CYP3A4 and transporter activities, undermining their utility for translational pharmacokinetic studies (Saito et al., 2025).

Breakthroughs in PSC-Derived Intestinal Organoids

Recent advances highlighted in a seminal study (European Journal of Cell Biology, 2025) have demonstrated that human induced pluripotent stem cell (hiPSC)-derived intestinal organoids can be generated using direct 3D cluster culture methods. These organoids faithfully reproduce the architecture and cell-type diversity of the native intestine, including enterocytes, goblet cells, enteroendocrine cells, and Paneth cells. Importantly, when exposed to Gastrin I (human), these organoids enable a precise interrogation of CCK2 receptor signaling and proton pump activity under near-physiological conditions.

Advanced Applications in Gastrointestinal Physiology and Pharmacokinetics

Modeling Gastrointestinal Disorder Mechanisms

Gastrin I (human) is pivotal for gastrointestinal disorder research, facilitating the modeling of acid hypersecretion syndromes (e.g., Zollinger-Ellison syndrome), peptic ulcer disease, and gastroesophageal reflux disease. By modulating CCK2 receptor signaling in hiPSC-derived organoids, researchers can unravel disease-specific alterations in acid secretion pathways and identify potential therapeutic targets.

Pharmacokinetic Studies and Drug Discovery

The integration of Gastrin I (human) into advanced organoid platforms is transforming drug absorption and metabolism research. Unlike traditional models, hiPSC-derived intestinal organoids possess active CYP450 enzymes and drug transporters, enabling realistic simulation of oral drug pharmacokinetics. By combining Gastrin I (human) stimulation with pharmacokinetic assays, investigators can evaluate the impact of gastric acid modulation on drug absorption, stability, and metabolism—critical for optimizing oral therapeutics (Saito et al., 2025).

Bridging Basic and Translational Research

This expanded capability positions Gastrin I (human) not just as a tool for basic gastrointestinal physiology studies, but as an enabler of translational workflows that link bench discoveries to clinical development. For instance, the peptide’s application in organoid-based disease modeling can accelerate the identification of biomarkers and the screening of novel proton pump inhibitors or CCK2 receptor antagonists, bridging gaps in preclinical-to-clinical translation.

Content Differentiation: A Translational Perspective on Gastrin I (human)

While prior articles, such as "Gastrin I (human): Driving Innovation in High-Definition...", have explored the peptide’s mechanistic roles in hiPSC-derived models and its utility in advanced pharmacokinetic platforms, this article takes a step further by contextualizing Gastrin I (human) within the paradigm of translational medicine. We focus on how the peptide, when applied to next-generation human organoid systems, enables direct investigation of human-specific disease mechanisms and pharmacokinetic behaviors—an angle only alluded to in previous discussions.

In contrast to "Gastrin I (human): A High-Purity Regulator for Gastric Ac...", which details atomic mechanisms and integration into generic organoid workflows, our review emphasizes the peptide’s unique value in translational research—specifically, its role in linking molecular insights with therapeutic development pipelines. Furthermore, articles such as "Human Gastrin I Peptide: Precision Tool for GI Physiology..." underscore the high purity and receptor specificity of the peptide; we build upon these foundational concepts by highlighting the direct experimental advantages conferred by APExBIO’s ultra-pure B5358 formulation for reproducibility in complex organoid systems.

Quality Control and Experimental Considerations

Purity, Solubility, and Reproducibility

APExBIO’s Gastrin I (human) distinguishes itself through stringent purification (≥98% by HPLC, mass spectrometry) and robust solubility in DMSO, ensuring minimal batch-to-batch variability. This is particularly critical in organoid models, where even minor impurities can confound interpretations of receptor-mediated signal transduction or proton pump activation. The product’s lyophilized form and handling recommendations (desiccation at -20°C, prompt use of solutions) further safeguard experimental integrity.

Experimental Design for Organoid Applications

Successful implementation of Gastrin I (human) in organoid-based studies requires careful titration to match physiological concentrations and time-dependent protocols that recapitulate in vivo exposure. Researchers should exploit the peptide’s solubility in DMSO to achieve uniform dosing, and pair its administration with real-time readouts of acid secretion, calcium flux, or downstream kinase activation to fully elucidate CCK2 receptor signaling dynamics.

Conclusion and Future Outlook

Gastrin I (human) stands at the forefront of modern gastric acid secretion pathway research, offering unmatched precision for dissecting CCK2 receptor signaling and proton pump biology in human-specific models. The integration of this peptide into PSC-derived intestinal organoid systems represents a paradigm shift, enabling physiologically relevant, reproducible, and translationally meaningful studies of gastrointestinal function and disease. As organoid technologies continue to evolve and intersect with personalized medicine, APExBIO’s high-purity Gastrin I (human) (B5358) will remain a cornerstone reagent for both fundamental discovery and the development of next-generation therapeutics.

For researchers seeking to leverage the full potential of Gastrin I (human) in advanced gastrointestinal models, detailed product specifications and ordering information are available via APExBIO.